title: Anti-Aβ antibody target engagement: commentary regarding Watt et al. Acta Neuropathol 127:803-810 (2014).
authors.affiliation: Eli Lilly and Company, Indianapolis, IN, USA, siemers_eric_r@lilly.com.
authors.forename: Eric
authors.initials: E
authors.lastname: Siemers
authors.forename: Robert A
authors.initials: RA
authors.lastname: Dean
authors.forename: Ronald B
authors.initials: RB
authors.lastname: DeMattos
authors.forename: Michael L
authors.initials: ML
authors.lastname: Hutton
authors.forename: Kaj
authors.initials: K
authors.lastname: Blennow
authors.forename: Leslie M
authors.initials: LM
authors.lastname: Shaw
authors.forename: David M
authors.initials: DM
authors.lastname: Holtzman
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy*; D016229:Amyloid beta-Peptides / Q000378:metabolism*; D000818:Animals; D000906:Antibodies / Q000378:metabolism*; D005260:Female; D006801:Humans; D018697:Nootropic Agents / Q000494:pharmacology*
chemical_list: D016229:Amyloid beta-Peptides; D000906:Antibodies; D018697:Nootropic Agents